Influenza vaccines that better target the influenza surface protein called neuraminidase (NA) could offer broad protection against various influenza virus strains and lessen the severity of illness, according to new research published in Cell.
Current seasonal influenza vaccines mainly target a different, more abundant influenza surface protein called hemagglutinin (HA). However, because influenza vaccines offer varying and sometimes limited protection, scientists are exploring ways to improve vaccine effectiveness. The new research builds on previous studies of NA and was conducted by a team of scientists including investigators from the Centers of Excellence for Influenza Research and Surveillance (CEIRS)program, which is organized and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Investigators analyzed blood samples from people vaccinated against influenza and people diagnosed with either the 2009 H1N1 influenza virus or H3N2 influenza viruses. The volunteers were recruited for this study or had taken part in prior influenza research studies. The analyses indicate that influenza vaccines rarely induce NA-reactive antibodies, whereas natural influenza infection induces these types of antibodies at least as often as they induce HA-reactive antibodies. Additional studies in mice reinforced the human data, indicating that current influenza vaccines do not induce NA-reactive antibodies efficiently.
Additional laboratory experiments show that the NA-reactive antibodies induced during natural influenza infection are broadly reactive, meaning they could potentially protect against diverse strains of influenza. To test this theory, scientists isolated NA-reactive monoclonal antibodies from the H3N2 and H1N1 influenza patients (N2-reactive antibodies and N1-reactive antibodies, respectively). They administered 13 N2-reactive antibodies to mice and subsequently infected the mice with a different H3N2 virus strain. Eleven of the 13 N2-reactive antibodies partially or fully protected the mice. They also administered eight N1-reactive antibodies to mice and subsequently infected the mice with a similar H1N1 virus strain or an H5N1-like virus strain. Four of the eight antibodies completely protected the mice against both virus strains.
The authors note that the findings suggest that influenza vaccines should be optimized to better target NA for broad protection against diverse influenza strains. In this regard, NIAID is supporting research to characterize NA responses in infected and vaccinated individuals and to determine the mechanism of action of NA protection. NIAID also supports “NAction!” a CEIRS working group that identifies knowledge gaps in our understanding of NA and sets NA research priorities for improved influenza vaccines. These efforts contribute to NIAID’s larger plan to develop a universal influenza vaccine—a vaccine that can durably protect all age groups against multiple influenza virus strains.
The Latest on: Influenza
via Google News
The Latest on: Influenza
- The Flu Blues: Influenza and Vaccineson October 15, 2019 at 5:51 pm
Although flu vaccines are generally effective, Whittaker said that it can be difficult to ensure that a seasonal flu vaccine will mimic the right strain. “[Influenza] is tricky to manage because it ...
- Novavax Initiates Pivotal Phase 3 Clinical Trial of NanoFlu Influenza Vaccine in Older Adultson October 15, 2019 at 4:00 am
Oct. 15, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the initiation ...
- Influenza Vaccine Market Trends-2019: Development, Raw Materials, Price, Supply-Demand, and End User Analysis, Outlook for 2019- 2023on October 14, 2019 at 4:53 pm
(MENAFN - The Expresswire) Influenza Vaccine Market Trends-2019: Development, Raw Materials, Price, Supply-Demand, and End User Analysis, Outlook for 2019- 2023 "Influenza Vaccine Market report ...
- 150th anniversary: Influenza grips Fijion October 14, 2019 at 4:23 pm
On November 18, 1918, one of The Fiji Times articles said: “As a result of the outbreak of influenza in Suva, six Fijians who contracted it have died at the Colonial Hospital.” Word was also received ...
- Influenza Diagnostics Market Is Likely To Reach $3.3 Billion By 2024: Grand View Research, Inc.on October 14, 2019 at 1:05 am
According to report published by Grand View Research,emergence of technologically advanced diagnostic tests with shorter turnaround time; initiatives by regulatory bodies, such as CDC's seasonal ...
- 600 pregnant Wellington women needed for international influenza studyon October 13, 2019 at 2:11 pm
The study will be done in conjunction with others in Los Angeles and Nicaragua's capital, Managua. The seven-year research award gave credit to the country's influenza research to date, McLea said.
- Influenza vaccines free for those at high riskon October 13, 2019 at 5:06 am
The Ministry of Health and Prevention (Mohap) launched the national seasonal influenza awareness campaign on Sunday and announced free-of-charge vaccinations, beginning this month, for those at high ...
- Seniors Educated About Influenzaon October 11, 2019 at 10:03 am
Because people aged 65 and older are in a higher risk for influenza (the other is children 5 and younger), Community Health Nurse Krista Timken spoke to seniors at the Glastonbury Senior Center on Oct ...
- CDC: Seasonal influenza viruses circulating in southern hemisphereon October 11, 2019 at 8:54 am
(HealthDay)—Seasonal influenza viruses are circulating widely in the Southern Hemisphere, but influenza activity is currently low in the United States, according to research published in the Oct. 11 ...
via Bing News